Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1987 1
1988 2
1989 1
1990 1
1991 3
1992 5
1993 5
1994 10
1995 9
1996 13
1997 13
1998 34
1999 65
2000 74
2001 68
2002 82
2003 83
2004 92
2005 105
2006 110
2007 97
2008 104
2009 101
2010 118
2011 96
2012 106
2013 100
2014 112
2015 97
2016 123
2017 104
2018 96
2019 96
2020 112
2021 121
2022 135
2023 138
2024 163
2025 62

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,597 results

Results by year

Filters applied: . Clear all
Page 1
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P; AGA Clinical Guidelines Committee. Grunvald E, et al. Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20. Gastroenterology. 2022. PMID: 36273831
METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis of the f …
METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Developme …
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ, Lee SY. Tak YJ, et al. Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. Curr Obes Rep. 2021. PMID: 33410104 Free PMC article. Review.
RECENT FINDINGS: Recent meta-analyses of new anti-obesity drugs and their weight-loss efficacy have shown that the overall placebo-subtracted weight reduction (%) for at least 12 months ranged from 2.9 to 6.8% for the following drugs: phentermine/topiramate (6.8%), liraglutide (5 …
RECENT FINDINGS: Recent meta-analyses of new anti-obesity drugs and their weight-loss efficacy have shown that the overall placebo-subtracte …
Orlistat-associated adverse effects and drug interactions: a critical review.
Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Filippatos TD, et al. Drug Saf. 2008;31(1):53-65. doi: 10.2165/00002018-200831010-00005. Drug Saf. 2008. PMID: 18095746 Review.
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. ...Orlistat has a beneficial effect on carbohydrate metabolism. No significant effect on cancer risk has been reported with orlistat.Orlistat interferes with the …
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. ...Orlistat has a beneficial effect …
Weight Loss Pharmacotherapy: Current and Future Therapies.
Jordan G, Young S, Alemán JO. Jordan G, et al. Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006. Gastrointest Endosc Clin N Am. 2024. PMID: 39277293 Review.
There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0 mg, and semaglutide 2.4 mg. ...
There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramat …
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Son JW, Kim S. Son JW, et al. Diabetes Metab J. 2020 Dec;44(6):802-818. doi: 10.4093/dmj.2020.0258. Epub 2020 Dec 23. Diabetes Metab J. 2020. PMID: 33389955 Free PMC article. Review.
As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g., diet, exercise, and behavioral therapy), pharmacological approaches to the treatment of obesity should be considered as an adjunct thera …
As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e. …
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.
Tang W, Sun G, Ji GW, Feng T, Zhang Q, Cao H, Wu W, Zhang X, Liu C, Liu H, Huang T, Liu L, Xia Y, Wang X. Tang W, et al. J Immunother Cancer. 2023 Nov 24;11(11):e007030. doi: 10.1136/jitc-2023-007030. J Immunother Cancer. 2023. PMID: 38007237 Free PMC article.
In further clinical translation, we found that orlistat significantly inhibited FABP1 activity, while the combination of anti-programmed cell death 1(PD-1) could synergistically treat HCC progression. Liposomes loaded with orlistat and connected with IR780 probe cou …
In further clinical translation, we found that orlistat significantly inhibited FABP1 activity, while the combination of anti-program …
Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q, Zhou Y, Feng X, Gao Y, Huang C, Yao X. Zhang Q, et al. Biomed Pharmacother. 2022 Sep;153:113426. doi: 10.1016/j.biopha.2022.113426. Epub 2022 Jul 21. Biomed Pharmacother. 2022. PMID: 36017794 Free article.
The failure of and resistance to oxaliplatin (OXA)-based chemotherapies may lead to poor prognosis in colorectal cancer (CRC) patients. It has been reported that orlistat (Orli) exhibits potent antitumor effects in several malignant tumors. Here, we identified that OXA in …
The failure of and resistance to oxaliplatin (OXA)-based chemotherapies may lead to poor prognosis in colorectal cancer (CRC) patients. It h …
Orlistat.
McNeely W, Benfield P. McNeely W, et al. Drugs. 1998 Aug;56(2):241-9; discussion 250. doi: 10.2165/00003495-199856020-00007. Drugs. 1998. PMID: 9711448 Review.
In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was further reduced or maintained in the second year, when a eucaloric diet was allowed, in orlistat but not placebo recipients. A greater pr …
In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was furt …
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L, Cheng Z, Zhang J, Li J, Xu X, Wu J, Yang M, Feng J, Guo C. Li Y, et al. J Exp Clin Cancer Res. 2023 Jan 6;42(1):6. doi: 10.1186/s13046-022-02567-z. J Exp Clin Cancer Res. 2023. PMID: 36604718 Free PMC article.
Both in vitro and in vivo studies were conducted to examine the antitumor effects of the combination of orlistat and sorafenib and CalcuSyn software was used to calculate the combination index. ...CONCLUSION: Targeting the FASN/HIF1alpha/SLC7A11 pathway resensitized HCC ce …
Both in vitro and in vivo studies were conducted to examine the antitumor effects of the combination of orlistat and sorafenib and Ca …
Orlistat.
Wong NN, Cheng-Lai A. Wong NN, et al. Heart Dis. 2000 Mar-Apr;2(2):174-81. Heart Dis. 2000. PMID: 11728255 Review.
Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the management of obesity. ...In addition, orlistat was found to have favorable effects on blood pressure and concentrations of serum lipid, gluc …
Obesity is a risk factor for cardiovascular disease. Orlistat is a gastric and pancreatic lipase inhibitor indicated for the manageme …
2,597 results